https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=11224

Elvitegravir / Cobicistat

Quetiapine

Evaluate the risk/benefit ratio. Dosage adjustment may be necessary.

No pharmaceutical opinion available for this interaction.

Mechanism

Elvitegravir / Cobicistat can inhibit the metabolism (CYP 3A4) and increase the plasma concentration of Quetiapine.

Elvitegravir / Cobicistat

Pharmacodynamic effects

–

Recommendations

–

Alternative solution(s)

–

Quetiapine

Pharmacodynamic effects

Possible increase of adverse effects.

Recommendations

Avoid association, if possible.

Otherwise use smaller doses. Monitor closely for signs and symptoms of toxicity and adjust dosage as a function of efficacy and tolerance.

ECG may be recommended especially for people at risk of prolonged QT interval (electrolyte disturbances, bradycardia, or use of other medications that can prolong the QT interval).

See comments for further details.

Alternative solution(s)

–

Monitor

Quetiapine adverse effects : drowsiness, sedation, dizziness, weight gain, dyslipidemia, abdominal pain, orthostatic hypotension, tachycardia.

Tests

–

Pharmacokinetic parameters

–

Comment

The Canadian product monograph suggests avoiding association or using smaller doses.
While the US monograph suggests reducing to 1/6 of the dose with potent CYP3A4 inhibitors due to the 6-fold increase in AUC observed with ketoconazole. The European monograph goes so far as to contraindicate this association.

Ref #2578 : Some cases have been reported in the literature concerning a possible interaction between protease inhibitors and quetiapine.

Ref #3045 : In a study with healthy subjects with multiple doses, ketoconazole resulted in an increase of quetiapine of the mean Cmax and AUC of 235% and 522% (6x), respectively, with a decrease in the mean oral clearance by 84%. The average half-life of quetiapine increased from 2.6 to 6.8 hours. See quetiapine + ketoconazole.

Ref #2731 and #2828 : Published case reports reported adverse events possibly associated with atazanavir/ritonavir and quetiapine.
Bipolar patient of 57 years observed a rapid and severe weight gain when quetiapine was associated with the antiretroviral therapy consisting of atazanavir and ritonavir. After stopping of both ritonavir and quetiapine weight came back as before.
A second patient of 32 years known for an anxiety disorder observed a problem of sedation and confusion when she added the combination of atazanavir/ritonavir to her anxiolytic therapy consisting of quetiapine. The symptoms resolved quickly after stopping quetiapine.
According to the Naranjo probability scale, it is possible that adverse effects are related to the interaction between quetiapine and the combination of atazanavir/ritonavir in the first case and probably the latter.
Another publication reported a coma and an increase in T1 / 2 life of quetiapine at 62.4 hours after administration of an overdose of quetiapine (8000 mg) in a patient who was under atazanavir/ritonavir.

Ref #2829 : Another case report was published about a patient who had a priapism that started 5-6 hours after ingestion of the co-administration of perphénadine, quetiapine and lopinavir/ritonavir. Priapism lasted 42 hours. The mechanism involved would be a rapid increase in plasma concentrations of neuroleptics in the presence of lopinavir/ritonavir.

Ref #2956 : Case of priapism reported. See boceprevir and quetiapine.

Comment
Reference
  • 2830
    Quetiapine (Seroquel), AstraZeneca, Ontario, Canada, 29 novembre 2021.
  • 2570
    Elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild), Gilead, Ontario, Canada, 17 septembre 2018.
  • 2956
    Hammond KP, Nielsen C, Linnebur SA, Langness JA, Ray G et al. Priapism Induced by Boceprevir-CYP3A4 Inhibition and α-Adrenergic Blockade: Case Report. Clinical Infectious Diseases, 2014; 58(1): e35-38.
  • 3044
    Quetiapine (Seroquel), AstraZeneca, Delaware USA, feb 2017.
  • 2731
    Pollack TM, McCoy C, Stead W. Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients. Pharmacotherapy, 2009, 29(11): 1386-1391.
  • 2828
    Hantson P, Di Fazio V, Wallemacq P. Toxicokinetic interaction between quetiapine and antiretroviral therapy following quetiapine overdose. Drug Metab Lett 2010;4(1):7-8.
  • 2829
    Geraci MJ, McCoy SL, Crum PM, et al. Antipsychoticinduced priapism in an HIV patient : a cytochrome P450-mediated drug interaction. Int J Emerg Med 2010;3(2):81-4.
  • 2578
    Hill L and Lee KC. Pharmacotherapy considerations in patients with HIV and psychiatric disorders : focus on antidepressants and antipsychotics. The annals of pharmacotherapy. 2013;47:75-89.
  • 3045
    Grimm S, Richtand NM, Winter HR, Stams KR and SB Reele. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol. Jan 2006; 61(1): 58–69.
  • 3144
    Monographie Européenne : quetiapine. UKPAR. Safeguarding public health. Juillet 2010.
  • 3281
    Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya), Gilead, Ontario, Canada, 6 août 2021.
  • 3534
    Ray WA, Chung CP, Murray KT, Hall K and Stein CM. Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death. N Engl J Med. 2009 Jan 15; 360(3): 225-235.
  • 3569
    Stäuble CK, Lampert ML, Mikoteit T, Hatzinger M, Hersberger KE, et al. Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report. Int J Mol Sci. 2021 Jun; 22(12): 6480.